D-0491-2019 Class III Terminated

Recalled by Valeant Pharmaceuticals North America LLC — Bridgewater, NJ

FDA drug recall D-0491-2019 was initiated by Valeant Pharmaceuticals North America LLC on Jan 30, 2019 and is designated Class III. Reason for recall: Failed Dissolution Specifications: high out of specification results for dissolution when measuring the amount of drug released at certain time points. The recall status is terminated (terminated Jul 8, 2020). Affected quantity: 23,884 bottles.

Recall details

Product Type
Drugs
Report Date
Feb 20, 2019
Initiation Date
Jan 30, 2019
Termination Date
Jul 8, 2020
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
23,884 bottles

Product description

Diltiazem HCl CD capsules, 360 mg, 90-count bottles, Rx Only, Manufactured for: Oceanside Pharmaceuticals, a division of Valeant Pharmaceuticals North America LLC, Bridgewater, NJ 08807 USA; By: Valeant Pharmaceuticals International, Inc., Steinbach, MB R5G 1Z7 Canada; NDC 68682-521-01.

Reason for recall

Failed Dissolution Specifications: high out of specification results for dissolution when measuring the amount of drug released at certain time points.

Distribution pattern

Nationwide in the USA and Puerto Rico

Code information

Lots: 18J035P, 18K094P, 18K093P, Exp 09/2020

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0491-2019
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0491-2019. Report a data issue: hello@regdatalab.com.